BB 3

Drug Profile

BB 3

Alternative Names: BB-3; Refanalin

Latest Information Update: 01 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Angion Biomedica
  • Class Small molecules
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal failure
  • Phase II Acute kidney injury
  • No development reported Heart failure
  • Discontinued Hepatic fibrosis; Myocardial infarction; Stroke

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Acute kidney injury (Prevention) in USA (IV) (NCT02771509)
  • 01 Jan 2016 Phase-III clinical trials in Renal failure in USA (IV) (NCT02474667)
  • 18 Aug 2015 BB 3 is still in phase II development for Renal failure/delayed graft function in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top